A brief historical background of the development of the theranostic approach in nuclear medicine is given and seven theranostic pairs of radionuclides, namely 44g Sc/ 47
Introduction
Radioactivity is unique in the sense that it can be routinely used in nuclear medicine both for diagnosis and therapy [1] . Each application, however, demands a special type of radionuclide, the choice being dependent on its decay properties. Thus, c-ray emitters like 99m Tc (T = 6.0 h), 123 I (T = 13.2 h) and 201 Tl (T = 3.06 d), and positron emitters, like 11 C (T = 20.4 min), 18 F (T = 109.6 min) and 68 Ga (T = 1.13 h) are commonly used in diagnostic studies utilizing Single Photon Emission Computed Tomography (SPECT) or Positron Emission Tomography (PET), respectively. As regards internal radionuclide therapy (endoradiotherapy), in general, radionuclides emitting low-range highly ionizing radiation, i.e., a-or b --particles, conversion and/or Auger electrons, are of great interest. The major problem in internal radiotherapy, however, has been the quantification of radiation dose caused to various organs, mainly due to uncertainties in the measurement of radioactivity from outside the body of the patient. Although in the case of a few therapeutic radionuclides, e.g., 131 I (T = 8.02 d) and 188 Re (T = 17.0 h), c-scanning or SPECT has been used to determine the radioactivity distribution in the body, the methodology lacks precision. The uncertainty in radioactivity distribution is still higher for radionuclides decaying by pure b --emission, e.g., 32 P (T = 14.3 d), 89 Sr (T = 50.5 d) and 90 Y (T = 2.7 d), because imaging is usually done through the use of bremsstrahlung.
In the early 1990 s, thoughts started developing in several laboratories to use a SPECT radionuclide as a surrogate of a therapeutic radionuclide [2] , e.g., 111 In (T = 2.8 d), a trivalent metal, as a surrogate of 90 Y, another trivalent metal. There has also been discussion about the use of several other metallic radionuclides [3] . However, none of those approaches provided patient-individual quantitative data on radiation doses. In 1992, a few researchers at the Forschungszentrum Jülich, Germany, came to the idea of combining PET and endoradiotherapy by using a pair of radionuclides of the same element, one emitting positrons and the other b -emitting radionuclide 86 Y (T = 14.7 h) was developed and produced in sufficient quantity [4, 5] and it was applied together with the b --emitting radionuclide 90 Y (T = 2.7 d) in a tumour patient study [6] . That investigation is regarded today as the beginning of the theranostic concept. The development of this concept has been recently described in detail [7] .
By administering to a specific patient a positron-emitting radioisotope of an element together with a therapeutic radioisotope of the same element (which emits b --or aparticles, or low-energy Auger/conversion electrons), it is possible to measure the uptake kinetics in an organ of the patient via PET imaging, thereby allowing an accurate dosimetric calculation, which leads to quantification of therapy. This concept is now called ''theranostic approach'' and it is finding increasing application. The methodology of using ''matched-pair'' of radionuclides in patient care studies is known as ''personalized medicine''.
There are several suitable or potentially suitable theranostic pairs of radionuclides, e.g. 44g Sc/ 47 Sc; 64 Cu/ 67 Cu; 68 Ga/ 67 Ga, 72 Tb/ 149 Tb. Some of them have already found application in clinical research while the others are being developed. In recent years there is also an increasing tendency to handle only one radionuclide as a theranostic agent, especially if it is readily available. One example is 177g Lu. The dosimetry is based on c-ray spectrometry or SPECT and the therapy effect is well known. However, in comparison to the PET technique, SPECT is not quantitative, though in recent years high-quality SPECT systems have been developed.
In this review we discuss seven rather established pairs of radionuclides where a combination of PET and internal radiotherapy is involved. Their production methods are described and the prospects of their availability on a clinical scale are considered.
Choice of radionuclides: decay data
The decay properties of the seven pairs of radionuclides under consideration in this review are given in Table 1 . The major decay data were taken from refs. [8-10] and they represent the commonly accepted values. Only in a few individual cases, e.g., 64 Cu and 124 I, own recently measured data [11] are given. The positron emission intensities for 83 Sr, 86 Y and 152 Tb are rather uncertain. The positron endpoint energy and the associated c-rays play important roles in PET measurements. Whereas a high positron endpoint energy affects the resolution of a scan, the c-rays present in the vicinity of the annihilation radiation may altogether distort the image. From this point of view the positron emitter 86 Y is far from ideal, but it could be used after many scattering corrections [12, 13] . There is some problem with 124 I as well, but the corrections needed are much smaller [12] [13] [14] . Somewhat similar result was obtained with 44g Sc [15] . The positron emitter 64 Cu is almost ideal for PET imaging because of its low positron endpoint energy and almost no emitted c-ray, the abundance of the 1346 keV c-ray being negligibly low. It has been therefore extensively used in PET studies related to radioimmunotherapy. As far as the other two b Tb has somewhat higher positron endpoint energy but since the associated crays are not too many, it has been used in PET measurements after applying scattering corrections similar to those in the case of 
Production methodologies
The development of production methodology of a novel radionuclide involves work in several directions, e.g., nuclear data, irradiation technology, chemical separation and quality control of the product. We consider several of those aspects below for each individual radionuclide. For a few radionuclides, some production details were recently reported [16, 17] . For those radionuclides, therefore, the present review gives only some updated information.
Theranostic pair 44g
Sc/ 47 Sc
The trivalent element scandium forms very useful metal complexes with many oxygen-containing bifunctional chelators. This pair of radionuclides is therefore of great potential value in theranostic investigations. Although the positron emitter 43 Sc (T = 3.9 h) is also very interesting and is presently attracting considerable attention, we limit our discussion to 44g Sc because it has been more thoroughly investigated.
Production of 44g Sc
For the production of the positron emitter Fig. 1 . The data for the (p,n) reaction were taken from refs. [25, 26, 28] whereby the Levkovskii data [26] were reduced by a factor of 0.82 [33] . The cross section data adopted for the (d,2n) reaction were from [30] and those for the (a,n) reaction from refs. [26, 31, 32] . Evidently, the yield from the (p,n) reaction is higher than that from the (d,2n) reaction up to about 30 MeV; thereafter the (d,2n) reaction appears to give a higher yield. The yield from the (a,n) process is much lower. In each case a highly 46 Ca in nat Ca is only 0.004%, so that an enriched target is absolutely necessary, which is very expensive, (b) the cross section of the (n, c) reaction is not high (see Table 2 ). Nonetheless, the methodology has been recently well developed by using a 31.7% enriched 46 Ca(NO 3 ) 2 target and irradiating it at the neutron high flux reactor in Grenoble. The 47 Sc activity was separated from calcium by column chromatography, similar to the method developed for the separation of 44 Sc from a 44 Ca target (see above). From a 1 mg 46 Ca target, a batch yield of 600 MBq of 47 Sc was obtained. A higher yield could be achieved by increasing the amount of the target material. Besides the neutron activation of 46 Ca, the production of 47 Ca is also being investigated via the 48 Ca(c,n)-route [64, 65] , especially in view of the increasing potential of high power electron linear accelerators. Irradiations were done with photons obtained from a 40 MeV, 1 kW beam of electrons on a convertor, and the radioactivity of the product 47 Ca was assayed. Further simulation, benchmarking and separation studies are continuing.
The Sc was obtained in low yield which was, however, sufficient for a preclinical study. In the latter case [66] , only the (p,2n) reaction cross section was measured.
Thus, in summary, considerable effort is presently being devoted to obtain high-quality 47 Sc in quantities sufficient for medical applications. In particular the photon induced reactions are receiving great attention. Theranostic pair 64 Cu/ 67 Cu
The element copper has a versatile co-ordination chemistry. In the no-carrier-added form copper radioisotopes are able to bind with biologically relevant small molecules as well as with some antibodies and proteins. It is thus very suitable for preparing metal-chelates for medical use [67, 68] . Two positron emitters of copper, namely 61 Cu (T = 3.4 h) and 64 Cu (T = 12.7 h), have been used in PET studies. For theranostic applications, however, the radionuclide 64 Cu appears to be more suitable because of its longer half-life. We therefore concentrated on this radionuclide.
Production of 64 Cu
Several routes have been investigated for the production of no-carrier-added 64 Cu. The oldest among them is the 64 Zn(n,p) 64 Cu reaction in a nuclear reactor (for a brief summary see [69] [70] [71] ). The fission neutron spectrum averaged cross section (r FS ) amounts to 31 ± 2.3 mb [62] and sufficient quantities of 64 Cu could be produced in a medium to high-flux reactor. The purity of the product achieved, however, did not meet the stringent demands for medical applications. In recent years some further efforts have been made to produce better quality 64 Cu via the above reaction in a nuclear reactor [70, 71] , in particular by using 99.4% enriched 64 ZnO as target material in a thermal neutron shielded sample holder and efficient separation methods for radiocopper [71] . Furthermore, accelerator produced neutrons have also been used, e.g. d(Be) break up neutrons [72] or 14 MeV neutrons [73] . In the latter two cases the (n,p) reaction cross section is higher. However, due to low neutron fluxes the yield of 64 Cu was low. The emphasis regarding the production of 64 Cu got shifted over the last several years from a reactor to a cyclotron. Proton and deuteron induced reactions on several target isotopes, especially the reactions 64 Ni(p,n) 64 Cu, 64 Ni(d,2n) 64 Cu, 68 Zn(p,an) 64 Cu, 66 Zn(p,2pn) 64 Cu, 64 Zn(d,2p) 64 Cu and 66 Zn(d,a) 64 Cu were investigated till 2009 over a wide energy range of up to 80 MeV using highly enriched target isotopes, with the aim of obtaining data for the production of 64 Cu. Based on a critical analysis of the published nuclear reaction cross section data, Aslam et al. [74] presented a comparison of the various production reactions of 64 Cu and came to the conclusion that the 64 Ni(p,n) 64 Cu reaction over the energy range of E p-= 12 ? 8 MeV would be the best choice. The calculated thick target yield amounts to 304 MBq lA -1 h -1 (for 1 h irradiation) and no radionuclidic impurity occurs. In recent years some further measurements near the threshold of the 64 Ni(p,n) 64 Cu reaction have been carried out [75] and the reaction 67 Zn(p,a) 64 Cu has also been studied [76] . Furthermore, in connection with the specific activity of 64 Cu, the formation of non-radioactive copper during the production of 64 Cu via proton and deuteron-induced reactions on enriched 64 Ni has also been considered [77] . The nuclear process 64 Ni(p,n) 64 Cu, developed at the Forschungszentrum Jülich [78] , has now become the standard procedure for the production of 64 Cu. The major features were the preparation of a target via electrodeposition of 64 Ni on a Au backing, a clean separation of 64 Cu via ion-exchange chromatography, and an efficient recovery of the enriched target material. The technology was further developed in some laboratories [79] [80] [81] and batch yields of up to 40 GBq of 64 Cu were achieved. Several other optimization studies have also been performed [82] [83] [84] [85] [86] [87] . Many small hospital-based laboratories are now producing this radionuclide in amounts sufficient for local use. A few newer developments are related to more efficient chemical separation and purification of 64 Cu [88] [89] [90] [91] . There has been some emphasis on automation of the production procedure as well [92] [93] [94] [95] [96] . Thus, considerable interest has been aroused in recent years in the production of 64 Cu via this route. Due to the increasing demand for this radionuclide, on one hand solution targets similar to those for 44g Sc mentioned above are being developed [97] and, on the other, a commercialization of the process is being pursued. However, it should be mentioned that small amounts of 64 Cu have also been produced via the nuclear processes 64 Zn(d,2p) 64 Cu [98, 99] and 68 Zn(p,an) 64 Cu [100] [101] [102] [103] , the latter partly as a by-product in the production of 67 Ga via the 68 Zn(p,2n) 67 Ga reaction.
Production of 67 Cu
The production of the therapeutic radionuclide 67 Cu (T = 2.58 d) in no-carrier-added form has also been under consideration for more than 40 years and the knowledge available till 2011 was critically reviewed [104] . A few other later reviews dealt with the newer information [17, [105] [106] [107] . In this work therefore only some salient features are mentioned.
Similar to 64 Cu, the production of 67 Cu in neutron induced reactions, especially in a nuclear reactor via the 67 Zn(n,p) 67 Cu reaction (r FS = 1.07 ± 0.04 mb) has received some new attention [69, 71] , in particular by using 93% enriched 67 ZnO as target material [71] . The same threshold reaction has also been investigated with 14 MeV neutrons; however, by using a nat ZnO target [73] . A yet another method making use of the 68 Zn(n,np) 67 Cu reaction induced by fast neutrons, generated by breakup of 40 MeV deuterons on a graphite target, has also been utilized [108] . In those two works [73, 108] the fundamental separation and purification procedures were established. The 67 Cu obtained via the latter process using a 99.29% enriched 68 ZnO target was shown to be suitable for preclinical studies [109] . For large scale production, however, further development work using high neutron fluxes is needed. Another reaction which has been under investigation for a long time is the 68 Zn(c,p) 67 Cu process. In one early study nat Zn was used as target material [110] and in another 98.97% enriched 68 ZnO was employed [111] . In both cases chemical separation of the product 67 Cu was carried out. The batch yield achieved was up to 185 MBq but the chemical purity would not meet the standard required today. With the increasing significance of 67 Cu combined with the development of powerful electron accelerators, in recent years the efforts to utilize the 68 Zn(c,p) 67 Cu reaction for 67 Cu production have been intensified [64, [112] [113] [114] [115] . Production yields of 67 Cu have been measured experimentally and compared with theoretically calculated values [112, 113] , extensive purification methodology was developed [114] , simulation studies were performed and predicted activities were verified with experimental data [64, 115] . The yield of 67 Cu achieved amounts to about 1 MBq g -1 kW -1 h -1 . Thus, tens of MBq of 67 Cu can easily be produced. It is expected that with further intensification of technological efforts to develop high-intensity accelerators (possibly up to 100 kW power), it should be possible to produce 67 Cu in GBq quantities. In addition to the neutron and photon induced reactions described above for the production of 67 Cu, considerable effort has been invested over the years to make use of charged-particle induced reactions as well. The four nuclear processes investigated are listed in Table 3 . The suitable energy ranges and the calculated thick target yields are based on evaluated excitation functions [116] and a few other measurements. However, it should be mentioned that a new measurement on the 68 Zn(p,2p) 67 Cu reaction [117] gives cross section values which are lower than the evaluated data up to 60 MeV by about 10%. If those values are accepted, the calculated yield of 67 Cu would decrease slightly. The yield values for the 70 Zn(d,an) 67 Cu and 64 Ni(a,p) 67 Cu reactions given in Table 3 were derived from individual experimental cross section curves, for the former reaction from Ref. [118] and for the latter from Refs. [119, 120] .
As far as the practical production of 67 Cu is concerned, in the case of the 70 Zn(p,a) 67 Cu reaction two studies were performed, one using a 99.7% enriched 70 ZnO target [121] and the other using a 70% enriched 70 Zn electroplated target [122] . The separation yields were comparable but, as understandable, the radionuclidic purity of 67 Cu achieved was higher in the first study due to the higher enrichment of the target. The batch yield of 67 Cu obtained via this production route was, however, quite low. With regard to the 70 Zn(d,an) 67 Cu reaction, the production test involved only low current irradiation of a very thin target and so the batch yield achieved was very low [118] . There is the possibility to produce larger quantities of 67 Cu if thicker targets are used. The reaction 64 Ni(a,p) 67 Cu also leads to a relatively low yield of 67 Cu because of the low cross section and the low range of a-particles. Nonetheless, a suitable target was prepared and, after a 7 h irradiation with 36 MeV a-particles at 15 lA, followed by chemical separation, a total of 55 MBq of 67 Cu was achieved [123] . The product was chemically very pure and was used in preclinical studies [123] . The level of 64 Cu impurity was, however, somewhat high.
In contrast to the above mentioned three low yield processes, the reaction 68 Zn(p,2p) 67 Cu at intermediate energies leads to a much higher yield. It has therefore been receiving more attention. It was originally utilized for production of 67 Cu by irradiation with protons of energies about 180 MeV followed by chemical separation [48, 61, 124] . The yield was very high but the specific activity was low. Later investigations concentrated more over the energy region up to 70 MeV, utilizing highly enriched 68 Zn as target material and extensive chemical processing [125] [126] [127] . Further extensive work has recently been reported using about 100 MeV protons [128] . The suggested production energy range is, however, E p = 70 ? 30 MeV [105] ; at higher energies a considerable amount of inactive 65 Cu is formed via the 68 Zn(p,2p2n) 65 Cu reaction which decreases the specific activity of 67 Cu. Using an incident proton energy of about 92 MeV, batch yields of a few GBq of 67 Cu have been achieved at BNL. However, the product contains about 5 times more 64 Cu than 67 Cu. Thus further optimization work utilizing lower proton energies is needed. A further newer approach is to harvest 67 Cu from the cooling loop of the Facility for Rare Isotopes (FRIB) presently under construction; some preliminary results have been obtained by analysis of a few samples from the aqueous beam stop at the National Superconducting Cyclotron Laboratory (NSCL) [129] .
From the above discussion it is obvious that the development of production methods of 67 Cu is of great timely interest because it is one of the most important theranostic radionuclides. Diversified efforts are underway to obtain it in sufficient quantity and good quality for medical applications.
Theranostic pair 83 Sr/ 89 Sr
Strontium is an important bone seeking element. The radionuclides of strontium could therefore be used in diagnostic and therapeutic studies related to bone. The b --emitting 89 Sr (T = 50.5 d) is one of the earliest known radionuclides to cure metastases in bone. It also finds application in palliation studies. The b ? -emitting analogue 83 Sr (T = 32.4 h) should be suitable for theranostic application. As far as we know, to date no PET measurement has been reported using 83 Sr; yet its decay properties suggest that it is potentially suitable.
Production of 83 Sr
Regarding the production of no-carrier-added 83 Sr, excitation functions were measured for the 85 Fig. 2 . The optimum energy range for the production of 83 Sr is E p-= 37 ? 30 MeV, whereby the yield of 83 Sr amounts to 160 MBq lA -1 h -1 (for 1 h irradiation) and the levels of the two long-lived impurities 85 Sr (T 1/2 = 64.9 d) and 82 Sr (T 1/2 = 25.3 d) are 0.24% and 0.04%, respectively. A similar analysis for the 3 He-particle induced reactions on 82 Kr showed that the optimum energy range for the production of 83 Sr is E 3 He = 18 ? 10 MeV, whereby the yield of 83 Sr amounts to 5.1 MBq lA -1 h -1 (for 1 h irradiation) and the level of the only impurity 82 Sr is 0.20%. The method of choice for the production of 83 Sr is thus the 85 Rb(p,3n)-reaction, although the availability of 40 MeV protons is often a problem.
Irradiations of several targets with low beam currents of 40 MeV protons and 18 MeV
3 He-particles were carried out to measure experimental thick target yields. In the former case, pressed 85 RbCl pellets absorbing about 5 MeV of the proton beam were used and, in the latter, 82 Kr gas absorbing about 8 MeV of the 3 He-particle energy was irradiated in a special target system [133] . Highly efficient separation methods, using high performance liquid chromatography, were developed to obtain radiostrontium of high quality [131] . The results were compared with the theoretical data. The radionuclide 83 Sr was obtained in 82 Rb generator system), except that the proton energy incident on the 85 RbCl target should be 40 MeV instead of 70 MeV used in the 82 Sr production.
Production of 89 Sr
As far as the production of the therapeutic radionuclide 89 Sr is concerned, some use has been made of the 88 Sr(n,c) 89 Sr reaction. However, due to the very low specific activity, the product 89 SrCl 2 has been used only in palliative therapy of malignant metastases to the skeleton. For preparation of radiopharmaceuticals with high specific activity, a production route involving the neutron threshold reaction 89 Y(n,p) 89 Sr has been developed. The cross section averaged for the fission neutron spectrum is low (r FS = 0.31 ± 0.06 mb [62] ); therefore long irradiations are needed. The target material consisting of Y 2 O 3 powder, pressed to a pellet, is placed in an Al capsule. The irradiation is done for several weeks at a high fast neutron flux of 1-2 9 10 15 n cm -2 s -1 . Thereafter the chemical processing starts by dissolving the irradiated target in HNO 3 and extracting the bulk of yttrium in tributylphosphate. The purification of 89 Sr is done by incorporating several cationexchange chromatographic steps. The finally purified product is then obtained as 89 In recent years the separation of radioiodine from aparticle irradiated antimony was also investigated using solvent extraction and ion-chromatographic techniques [151] [152] [153] . The radionuclidic purity of the product achieved was quite high. However, due to the low batch yield of 124 I, those methods have not found much practical application.
As far as the production of 131 I (T = 8.02 d) is concerned, the methodology is well established [cf. 154] . It is a reactor radionuclide and is produced either via the fission process (as a subsidiary of 99 161 Tb (T = 6.9 d) as well as to the a-particle emitting therapeutic radionuclide 149 Tb (T = 4.1 h), whose potential in therapy was first suggested by Allen and Blagojevic [155] . In fact these three radionuclides together with the Auger electron emitter 155 Tb (T = 5.3 d) make the element terbium very versatile for medical applications, somewhat similar to copper and iodine.
Development of 152
Tb and 149 Tb
Work on the development of the b ? -emitter 152 Tb and the a-particle emitter 149 Tb has been going on for quite some time and two rather uncommon reactions have been investigated for their production.
(a) Heavy-ion induced reactions, first studied in Sydney [156, 157] . Using a natural Nd target, 152 Dy. The product 152 Dy decays with a half-life of 2.4 h to 152 Tb. After irradiation the thick Nd metal target was therefore allowed to decay for about 12 h, thereafter it was dissolved in 6 M HNO 3 , evaporated to dryness and the residue redissolved in ahydroxyisobutyric acid (a-HIBA). The separation of no-carrier added 152 Tb was then achieved through cation-exchange chromatography. The batch yield of 152 Tb amounted to a few MBq. It was sufficient for tracer studies but not for a PET phantom measurement. In the same Nd target irradiated with 12 C ions, the a-particle emitting 149 Tb was formed via the 142 Nd( 12 C, 5n) 149 Dy ? 149 Tb process. Its batch yield amounted to a few MBq [157] . (b) Spallation reaction, first studied at CERN [156] . A tantalum foil was irradiated with 1000 MeV protons. The spallation products were released from the target at 2400°C. The ionized products were separated electromagnetically at the ISOLDE facility. The spallation products of mass number 152 were collected and subjected to a two-step separation procedure, similar to the one used in the separation of 86 Y [5] , viz. at first coprecipitation of radioterbium with La(OH) 3 , then removal of radioterbium from lanthanum by cation-exchange chromatography. The batch yield of 152 Tb amounted to 770 MBq [156] . A PET phantom measurement demonstrated the feasibility of using 152 Tb for monitoring the behavior of therapeutic terbium radionuclides [156] .
Following the successful production of 152 Tb via the spallation process, several optimization studies and further development work were carried out, in particular with regard to on-line mass separation [158, 159] . To demonstrate the utility of 152 Tb, a proof of concept study was performed with 152 Tb-labelled folate in a mouse, bearing folate receptor (FR)-positive tumours [158] . A more detailed in vivo imaging study using several other 152 Tblabelled compounds showed the potential of this radionuclide for PET studies [159] . Very recently the first application of this positron emitter in human PET/CT has been convincingly demonstrated [160] . The significance of this radionuclide is thus increasing.
Besides the application of the spallation process to the production of 152 Tb, many investigations on other possible production reactions have also been carried out. They deal either with cross section measurements of proton and deuteron induced reactions on gadolinium and dysprosium [161] [162] [163] [164] [165] [166] Fig. 3 , which has been adapted from the data of Steyn et al. [162] . The cross section of the 155 Gd(p,4n) 152 Tb reaction is fairly high and over the energy range of E p = 50 ? 30 MeV, the calculated yield of 152 Tb amounts to about 1.45 GBq lA -1 h -1 (for 1 h irradiation). Thus using an enriched 155 Gd target, in principle, it should be possible to produce 152 Tb in quantities sufficient for medical applications.
With regard to the production of the therapeutic radionuclides of terbium, the case of the a-particle emitter 149 Tb has been mentioned above. Its production in tracer quantities via the heavy-ion induced reaction was reported [157] . Subsequently, Beyer et al. [171, 172] produced this radionuclide on a clinical scale via spallation of tantalum with 1400 MeV protons in conjunction with on-line isotope separation at CERN, and demonstrated direct evidence for single cancer cell killing using 149 Tb-rituximab. In general, however, the availability of this radionuclide is rare. On the other hand the cross sections of a few (p,xn) reactions on a few gadolinium isotopes, leading to the formation of 149 Tb, have been described [162] . They appear to be interesting for production purposes but specific production methodology needs to be developed.
Production of 161 Tb
The production of the b --emitting therapeutic radionuclide 161 Tb is usually done in a nuclear reactor via the sequence 160 Gd(n,c) 161 Gd ! Tb from the gadolinium target is done by cationexchange chromatography with a-HIBA, followed by concentration of 161 Tb solution [158, 173, 174] , There is, however, some difficulty in the production process. The intermediate nuclide 161 Gd (T = 3.7 min) has a very high neutron capture cross section (r th & 20000 b) so that the formation of 161 Tb through the b --decay of 161 Gd is in strong competition with the formation of 162 Gd through the (n,c) reaction. A short irradiation with a high neutron flux is advantageous. In general, the radionuclide 161 Tb could be made available in sufficient quantities. 
Concluding remarks
The theranostic approach in nuclear medicine, i.e. administering to a specific person two radionuclides of the same element in the same chemical form, one emitting positrons and the other highly-ionizing low-range radiation to cause therapeutic effect, is gaining increasing significance because it constitutes ''personalized medicine''. In this review seven such pairs have been dealt with and their production methods have been discussed. The positron emitters 64 Cu, 86 Y and 124 I are well characterized and the respective production technology using the (p,n) reaction on the respective highly enriched target isotope is well developed. The positron emitter 44g Sc is presently attracting great attention. Though its clinical scale production has been achieved via two routes, namely the 44 Ti/ 44g Sc generator system and the direct production via the (p,n) reaction, further development work is necessary to ensure its large scale production. The basic methodology for production of the positron emitter 83 Sr has also been demonstrated but due to the need of an intermediate energy cyclotron, not much progress has been made with regard to its production on a clinical scale. The positron emitter 152 Tb is potentially very interesting. The production methodology developed so far, however, is rather exotic because it makes use of the spallation process in combination with on-line mass separation. Attempts are presently underway to produce it at an intermediate energy cyclotron/accelerator. All those positron emitters have either been shown to be, or are expected to be, suitable for PET measurements; only in the case of 86 Y the large number of associated c-rays cause some difficulty, but after proper corrections, the images can be satisfactorily interpreted.
Regarding the therapeutic radionuclides, 89 67 Cu are very interesting but difficult to produce. Therefore presently strong efforts are underway to produce them through neutron, photon and charged particle induced reactions.
In contrast to the above mentioned theranostic pairs of radionuclides consisting of a b
? -emitter and a b --emitter, the pair 152 Tb/ 149 Tb is unique in that the radionuclide 152 Tb is a b
? -emitter and 149 Tb is an a-emitter. The efficacy of 149 Tb for targeted a-therapy has been demonstrated but the exotic production route, involving spallation and on-line mass separation, makes its availability very rare. Further development work is called for.
Besides the 7 rather established theranostic pairs of radionuclides discussed in this review, the pair 72 As/ 77 As is in development [cf. 176-178]. Furthermore, there are 3 other pairs where the combination consists of a positron emitter and an Auger electron emitter as a therapeutic partner. They are 68 Ga/ 67 Ga, 110g In/ 111 In and 152 Tb/ 155 Tb. However, since Auger therapy using the radionuclides 67 Ga, 111 In and 155 Tb is still developing, those pairs have not been considered in this review.
In conclusion, it may be stated that the field of theranostics is attracting tremendous attention today, but the availability of the respective radionuclides plays a very important role. Concerted efforts are needed to produce several of the above mentioned radionuclides in quantities sufficient for clinical studies. Enhanced utilization of intermediate energy cyclotrons/accelerators would be very advantageous. Furthermore, for production of a few special radionuclides, use of powerful electron linear accelerators may be beneficial. Similarly, the use of some rather unconventional methods, like heavy-ion induced reactions and on-line mass separation of radioactive products, may also be worthwhile, especially for small scale production of some exotic radionuclides for tracer studies. 
